Doximity (NASDAQ:DOCS) Price Target Raised to $45.00
Doximity (NASDAQ:DOCS – Free Report) had its price target increased by Robert W. Baird from $41.00 to $45.00 in a research report released on Tuesday, Benzinga reports. They currently have an outperform rating on the stock. Other equities research analysts have also recently issued reports about the stock. Barclays increased their price objective on shares […]
Wedbush Raises Nuvalent (NASDAQ:NUVL) Price Target to $115.00
Nuvalent (NASDAQ:NUVL – Free Report) had its target price boosted by Wedbush from $99.00 to $115.00 in a research report released on Monday, Benzinga reports. Wedbush currently has an outperform rating on the stock. Several other brokerages have also weighed in on NUVL. Guggenheim upped their target price on shares of Nuvalent from $99.00 to […]
KLA (NASDAQ:KLAC) Price Target Cut to $900.00
KLA (NASDAQ:KLAC – Free Report) had its target price cut by Citigroup from $960.00 to $900.00 in a research report report published on Monday morning, Benzinga reports. They currently have a buy rating on the semiconductor company’s stock. A number of other analysts have also recently weighed in on the company. Evercore ISI upped their […]
PROCEPT BioRobotics (NASDAQ:PRCT) Price Target Raised to $99.00
PROCEPT BioRobotics (NASDAQ:PRCT – Free Report) had its target price raised by TD Cowen from $75.00 to $99.00 in a research note published on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock. Several other equities analysts also recently issued reports on the company. Truist Financial upped their target price […]
Summit Therapeutics (NASDAQ:SMMT) Price Target Raised to $45.00
Summit Therapeutics (NASDAQ:SMMT – Free Report) had its price target lifted by HC Wainwright from $30.00 to $45.00 in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. SMMT has been the topic of several other research reports. Stifel Nicolaus boosted their price target […]
T-Mobile US (NASDAQ:TMUS) Price Target Raised to $230.00
T-Mobile US (NASDAQ:TMUS – Free Report) had its price objective upped by KeyCorp from $190.00 to $230.00 in a research note issued to investors on Monday, Benzinga reports. KeyCorp currently has an overweight rating on the Wireless communications provider’s stock. A number of other brokerages also recently weighed in on TMUS. TD Cowen increased their […]
last updated on 20 Sep 10:34